Four states' Medicaid coverage end for weight-loss drugs linked to 84% GLP-1 prescription drop
A JAMA study links Medicaid withdrawal of GLP-1 weight-loss drug coverage in four states to an 84% relative drop in prescriptions. The finding shows how state coverage rules can rapidly affect access to obesity-related medications for Medicaid beneficiaries. It also highlights limits of prescription-level data for determining individual patient outcomes.
Researchers analyzed Medicaid prescription data from all 50 states and Washington, D.C., from January 2022 to March 2026, including fee-for-service and managed care claims. They compared four states that withdrew Medicaid coverage for GLP-1 drugs prescribed for weight loss on Jan. 1, 2026, with 10 states that kept coverage. In the withdrawal states, quarterly prescriptions fell from 2,914 to 421 per 100,000 Medicaid beneficiaries. In states that maintained coverage, the rate declined from 3,006 to 2,758 per 100,000.
The largest decline occurred in Pennsylvania, where the prescription rate fell 95.5%, followed by 88% in New Hampshire, 75.2% in California and 60.8% in South Carolina. Nationally, quarterly prescriptions for weight-loss-approved GLP-1 medications rose 5,858% from early 2022 to early 2026, while prescriptions for diabetes-approved GLP-1 medications rose 150%. Researchers estimated that 175,500 to 526,600 fewer Medicaid beneficiaries may have filled weight-loss GLP-1 prescriptions after coverage ended.
GLP-1 medications mimic a hormone that helps regulate appetite and blood sugar. Federal law allows states to exclude weight-loss drugs from Medicaid coverage, although Medicaid generally covers many outpatient medications. Since 2022, 17 state Medicaid programs have covered FDA-approved GLP-1 drugs for weight loss, often with prior authorization. The study found no statistically significant increase in diabetes GLP-1 use in the states that withdrew weight-loss coverage, suggesting patients did not broadly switch to those labels.
The findings are observational and cannot prove the coverage changes alone caused the drop; they also cannot show how many patients paid privately or went without. Because data were prescription-level, not patient-level, the estimate range reflects uncertainty. The study shows a strong temporal association between coverage withdrawal and lower GLP-1 dispensing among Medicaid beneficiaries. It adds evidence that access decisions can rapidly alter use of high-cost drugs for obesity-related care. The article did not report funding details.
Medicaid beneficiaries in states that ended coverage for FDA-approved GLP-1 weight-loss drugs may lose access to treatments linked to weight and cardiometabolic management, with prescription drops concentrated among low-income adults.
Sources (1)
- [1]Original source(https://medicalxpress.com/news/2026-11-medicaid-coverage-weight-loss-drugs.html)